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Abstract 40 
Canine infectious respiratory disease (CIRD) is a major cause of morbidity in dogs worldwide, and is 41 
associated with a number of new and emerging pathogens. In a large multi-centre European study the 42 
prevalences of four key emerging CIRD pathogens; canine respiratory coronavirus (CRCoV), canine 43 
pneumovirus (CnPnV), influenza A, and Mycoplasma cynos (M. cynos); were estimated, and risk factors for 44 
exposure, infection and clinical disease were investigated. 45 
CIRD affected 66% (381/572) of the dogs studied, including both pet and kennelled dogs. Disease 46 
occurrence and severity were significantly reduced in dogs vaccinated against classic CIRD agents, canine 47 
distemper virus (CDV), canine adenovirus 2 (CAV-2) and canine parainfluenza virus (CPIV), but substantial 48 
proportions (65.7%; 201/306) of vaccinated dogs remained affected. 49 
CRCoV and CnPnV were highly prevalent across the different dog populations, with overall seropositivity 50 
and detection rates of 47% and 7.7% for CRCoV, and 41.7% and 23.4% for CnPnV, respectively, and their 51 
presence was associated with increased occurrence and severity of clinical disease. Antibodies to CRCoV 52 
had a protective effect against CRCoV infection and more severe clinical signs of CIRD but antibodies to 53 
CnPnV did not.  54 
Involvement of M. cynos and influenza A in CIRD was less apparent. Despite 45% of dogs being seropositive 55 
for M. cynos, only 0.9% were PCR positive for M. cynos. Only 2.7% of dogs were seropositive for Influenza 56 
A, and none were positive by PCR. 57 
 58 
Keywords: canine respiratory coronavirus (CRCoV), canine pneumovirus (CnPnV), Canine influenza 59 
(CIV), Mycoplasma cynos, canine infectious respiratory disease (CIRD), Kennel cough. 60 
 61 
Introduction 62 
Canine infectious respiratory disease (CIRD) is a major cause of morbidity and an important welfare issue 63 
for kennelled dog populations worldwide. Characterised by clinical signs such as coughing, nasal discharge 64 
and dyspnoea, it can persist for several weeks, often resulting in severe disease, such as 65 
bronchopneumonia, and on occasions, lead to death or result in euthanasia (Appel and Binn, 1987).  66 
CIRD is a complex disease of multifactorial aetiology, where environmental, host and pathogen interactions 67 
influence disease susceptibility, severity and persistence. The pathogens traditionally associated with CIRD 68 
include canine parainfluenza virus (CPIV)(Appel and Percy, 1970), canine adenovirus type 2 (CAV-69 
2)(Ditchfield et al., 1962), and Bordetella bronchiseptica (Bb) (Bemis, 1992), which act sequentially or 70 
synergistically to cause disease. Several multivalent vaccines targeting these agents are available for 71 
routine vaccination (Day et al., 2016). However outbreaks of respiratory disease continue despite their use, 72 
resulting in expensive treatment costs and delays in rehoming or training (Erles et al., 2004). 73 
 Page 3 of 19 
 
In recent years a number of newly emerging pathogens, including canine respiratory coronavirus (CRCoV) 74 
(Erles et al., 2003), canine pneumovirus (CnPnV)(Renshaw et al., 2010), canine influenza H3N8 75 
(CIV)(Crawford et al., 2005), and Mycoplasma cynos (M. cynos)(Chalker et al., 2004), have been implicated 76 
in the development and persistence of CIRD, and are the subject of a  comprehensive review (Priestnall et 77 
al., 2014).  78 
Whilst it is widely recognised that these agents are all likely to play an important role in the onset or 79 
persistence of CIRD, the exact nature of their contribution to the pathogenesis of disease is yet to be 80 
determined. Most, if not all, studies to date have either been limited to the investigation of individual 81 
pathogens, or have been geographically restricted to a small number of kennels or a single outbreak, and 82 
no comprehensive survey of pet dogs has been completed. Thus the true extent of the prevalence of these 83 
novel agents, and the risk factors associated with exposure, infection and disease amongst different 84 
cohorts, have not been fully investigated. 85 
To help address this we present data from a large multi-centre European study in which the prevalences 86 
of four of the most important and recently identified emerging CIRD pathogens (CRCoV, CnPnV, CIV/ 87 
Influenza A and M. cynos) were estimated in both client-owned and kenneld dogs, and risk factors for 88 
exposure, infection and clinical disease were investigated. 89 
Methods 90 
Study design 91 
Samples and signalment data were collected from dogs in animal shelters, breeding kennels and academic 92 
or private veterinary clinics across Europe by collaborating Investigator Centres between October 2011 and 93 
August 2013. Dogs were actively recruited onto the study and sampled upon presentation to the 94 
veterinarian if they fell into one of three different clinical groups: (A) clinically unaffected but exposed to 95 
acute CIRD-affected dogs, (B) acute CIRD-affected dogs (0 to 3 days post onset of CIRD), or (C) convalescent 96 
CIRD-affected dogs (10-12 days post onset of CIRD). Details of the clinical grouping, source (i.e. client-97 
owned, shelter/ rehoming kennel, hospital, breeding kennel), recorded or estimated age, vaccination 98 
history for Bb, CPIV, CAV-2 and CDV, and clinical respiratory score (1-5) at the time of sample collection 99 
were recorded. Briefly the clinical scores described previously (Erles et al., 2003) were defined as: 1) no 100 
respiratory signs, 2) mild cough, 3) cough and nasal discharge, 4) cough and nasal discharge with depression 101 
and/ or inappetence, 5) cough and nasal discharge with depression and/ or inappetence and clinical signs 102 
of lower respiratory tract disease. 103 
 104 
Sampling: Viral nasal swabs (VNS) (Sterilin, UK), oropharyngeal Amies swabs (OAS) (Sterilin, UK) and serum 105 
samples were collected by local veterinary practitioners. All samples were collected as part of the standard 106 
veterinary diagnostic work-up for respiratory disease, and with informed consent for clinical research 107 
purposes (obtained by the attending veterinarian or collaborating centre). Samples were sent to 108 
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investigator centres across Europe, where they were appropriately stored, batched and shipped to the 109 
Royal Veterinary College for analysis. Duplicate samples were retained by collaborating investigator centres 110 
for their own research purposes and to date one study relating to a subset of these has been published 111 
(Decaro et al., 2016). The study was approved by the Royal Veterinary College’s Ethical Review Board.  112 
 113 
Detection of viral pathogens: 114 
The tip of each VNS was immersed in 1mL of DMEM medium (Sigma, Dorset, UK) and vigorously mixed. 115 
RNA was extracted from 200µl of the resulting swab fluid using the RNeasy Mini Kit (Qiagen, Crawley, UK) 116 
as recommended by the manufacturer, and eluted in 30µl of RNAse free water.  Five microliters of RNA 117 
was reverse transcribed into cDNA using Random Hexameres (Qiagen, Crawley, UK) and Improm II reverse 118 
transcriptase (Promega, Southampton, UK) according to the manufacturer’s protocol. CRCoV and CnPnV 119 
were detected as described previously by PCR (Erles et al., 2003) and real-time PCR (Mitchell et al., 2013b) 120 
respectively. Influenza A was detected using primers targeting a conserved region of the matrix gene (Ellis 121 
and Zambon, 2001), and the GoTaq polymerase system (Promega, Southampton, UK). 122 
  123 
Detection of Mycoplasma Spp: 124 
The tip of each OAS was placed in 1mL of Mycoplasma Experience (ME) liquid media (Mycoplasma 125 
Experience Ltd, Bletchingley UK), vigorously mixed and incubated at 37°C with 5% CO2.  Cultures were 126 
monitored daily (for up to 3 days) for signs of mycoplasma growth, as indicated by the presence of turbidity 127 
and or colour change. Once growth was observed, or at 3 days post inoculation with no apparent growth, 128 
the cells from 0.7mL of the liquid culture were pelleted and the DNA extracted using the DNeasy Mini Kit 129 
(Qiagen, Crawley, UK) as recommended by the manufacturer. DNA was eluted in 100µl of elution buffer 130 
and analysed using a pan-Mycoplasma Spp. PCR (Kobayashi et al., 1995), followed by a specific M. cynos 131 
PCR (Chalker et al., 2004) as previously described. 132 
Detection of antibodies:  133 
The antibody status of each dog for CRCoV, CnPnV and M. cynos was determined by ELISA using the 134 
following antigens: 135 
CRCoV ELISA Antigen: Recombinant CRCoV hemagglutinin esterase (HE) protein. The CRCoV HE protein 136 
(strain 4182) was expressed using the BacMagic™ recombinant baculovirus expression system (Merck, UK) 137 
at 5MOI in Spodoptera frugiperda 9 (SF9) cells. The antigen was prepared by lysing infected cells with lysis 138 
buffer (1% Igepal, 50mM NaH2PO4, 300mM NaCl, pH8) at 3 days post infection. The CRCoV HE antigen was 139 
standardised to a mock infected SF9 lysate which served as the control antigen, and 0.8 micrograms of total 140 
protein per well was used to coat the plate.   141 
 142 
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CnPnV ELISA Antigen: Freeze-dried murine pneumovirus and control antigen (Churchill Applied 143 
Biotechnology Ltd, Huntingdon) was prepared and used as described previously (Mitchell et al., 2013b).  144 
 145 
M. cynos ELISA Antigen: M. cynos (UK strain 491) cell pellets were washed three times in PBS, then 146 
resuspended in 5mL PBS, and freeze thawed.  Six nano-grams per well of total M. cynos protein in 50µl of 147 
PBS was used to coat the plate. Wells coated with PBS only were used as a background control.   148 
 149 
Briefly for each ELISA: Antigen was adsorbed overnight at 4˚C onto 96 well Nunc Maxisorb™ ELISA plates, 150 
and blocked with 5% milk in 0.05% PBS Tween. Serum samples were diluted 1:100 in blocking buffer and 151 
50µl dispensed in duplicate onto positive and control antigens and incubated at 37˚C for 1 hour. Following 152 
three washes with 0.05% PBST, the anti-dog IgG peroxidase conjugate (Sigma-Aldrich, Poole) secondary 153 
antibody  was diluted 1:2500 (CRCoV, CnPnV) or 1:5000 (M. cynos) in blocking buffer, and 50µl dispensed 154 
into each well and incubated. The plates were washed as before and bound antibody was detected using 155 
Sigma-Fast™ OPD peroxidase substrate (Sigma Aldrich, UK) according to the manufacturer’s instructions, 156 
and stopped with 2M H2SO4. Optical densities (OD) were measured at 490nm (Optimax automatic plate 157 
reader Molecular Devices, Wokingham). Positive and negative control sera were included in duplicate on 158 
each plate. For each serum sample, the average OD value for the negative antigen was subtracted from 159 
that of the positive antigen to give the average corrected OD value. The positive cut-off was defined as the 160 
average corrected OD value for a panel of reference serum (IgG negative for the antigen used) plus three 161 
times the standard deviation. Samples were considered positive if the ‘average corrected OD value’ was 162 
greater than or equal to the positive cut-off value for the ELISA. 163 
 164 
Influenza A ELISA:  The influenza antibody status was determined via two independent methods: 165 
1) Freeze-dried equine influenza A (H3N8 Miami) and control antigen (Churchill Applied B Biotechnology 166 
Ltd, Huntingdon) were used according the manufacturers recommendation and validated for use with 167 
canine samples using a panel of CIV (H3N8) positive and negative control serum (Zoetis Animal Health, 168 
Kalamazoo). The ELISA was performed as described above using a 1:2500 dilution of secondary antibody. 169 
2) The commercially available ID Screen Influenza A Antibody competition assay. The assay was performed 170 
according to the manufacturer’s protocol using a 1:10 dilution of canine serum as previously described 171 
(Pratelli and Colao, 2014). The assay was validated using the controls supplied with the kit and a panel 172 
of CIV (H3N8) positive and negative control serum (Zoetis Animal Health, Kalamazoo). 173 
Statistical analysis 174 
Data were recorded in Excel spreadsheets (Microsoft) and imported into Stata/SE 13 software (Statacorp) 175 
for analysis. Continuous variables were summarised using mean (standard deviation) if normally distributed 176 
and median (minimum, maximum) if non-normally distributed. Categorical variables were summarised 177 
using numbers and percent in each category and 95% confidence intervals (CI) around prevalence estimates 178 
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calculated using the Clopper-Pearson method. For the purposes of these analyses the clinical score variable 179 
was collapsed from the original categorisation of 1-5 (as detailed above) to a three-point ‘severity score’ of 180 
‘no disease’ (clinical score 1), ‘mild to moderate disease’ (clinical score 2 and 3) and ‘severe disease’ (clinical 181 
score 4 and 5).  The presence or absence of disease was also assessed, where the original clinical score of 182 
2-5 indicated the presence of disease and 1 indicated no disease. 183 
Variations in disease presence and severity by different factors (source, age, country and vaccination 184 
status), and variations in individual pathogen prevalence and seroprevalence in association with source, 185 
clinical group, disease presence and severity were examined using Chi-square/Fisher’s exact tests and 186 
univariable logistic regression. Multivariable logistic regression was used to examine relationships where 187 
more than one factor was significantly associated with the outcome at the 25% level (univariable screening 188 
p-value <0.25). 189 
Results  190 
Descriptive statistics  191 
Descriptive statistics relating to dogs and samples included in the study are summarised in Table 1. Samples 192 
and signalment data were obtained from 572 dogs (Table 1). Of these, 45.6% (n=261) were client-owned 193 
dogs, 46.2% (n=264) were from shelters and 8.2% (n=47) were from other sources (predominantly a single 194 
veterinary hospital). Overall, 24.1% (n=138) were clinically unaffected dogs that had been exposed to acute 195 
CIRD-affected dogs, 49.3% (n=282) were acute CIRD-affected dogs and 26.6% (n=152) were convalescent 196 
(10 days post onset of acute disease and may or may not have still been showing clinical signs of CIRD). 197 
Approximately equal proportions (~20%) of samples came from Italy, Greece, Hungary and France 198 
respectively with smaller proportions (~10%) from Spain and Netherlands. Estimated age was recorded for 199 
542 dogs and ranged from 5 weeks to 15 years with a median of 3 years.  200 
Clinical signs of respiratory disease were observed in 66.6% (n=381) of the 572 dogs. Just over half of the 201 
dogs (55.4%; n=317) showed signs of mild to moderate disease and 11.2% (n=64) showed signs of more 202 
severe disease.  203 
In total, 525 serum samples were examined for the presence of CRCoV, CnPnV, Influenza A or M.cynos 204 
antibodies and  559 viral nasal swabs (VNS) and 566 oropharyngeal Amies swabs (OAS) were analysed for 205 
the presence of the pathogens. 206 
The overall estimated seroprevalence in this study population was 47% (247/525; 95% CI: 42.7-51.4%) for 207 
CRCoV, 41.7% (219/525; 95% CI: 37.4-46.1%) for CnPnV, 45% (236/525; 95% CI: 40.6-49.3%) for M. cynos, 208 
and 2.7% (6/220; 95% CI: 1.0-5.8%) for Influenza A .  209 
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The overall estimated prevalence of each pathogen detected by PCR was 7.7% (43/559; 95% CI: 5.6-10.2%) 210 
for CRCoV, 23.4% (130/555; 95% CI: 20-27.2%) for CnPnV, 0.9% (n=5/566, CI) for M. cynos, and 0% (0/511) 211 
for Influenza A.  212 
Disease presence and severity was associated with source and a history of vaccination. 213 
Significant univariable variations in the presence and severity of disease were associated with source, 214 
country, vaccination and age (data not shown).  Dogs with clinical signs were significantly younger (median 215 
3 years; range 5 weeks to 15 years) than those without (median 4 years; range 5 weeks to 15 years) 216 
(p=0.003), with an inverse relationship between age and disease severity.  Whilst clinical disease was clearly 217 
prevalent amongst dogs both with and without a history of vaccination (Bb, CPIV, CAV-2 and CDV) the odds 218 
of disease were significantly reduced in dogs vaccinated against CPIV, CAV-2, and CDV, but not Bb.  219 
Variations in disease presence in association with country and age were no longer significant in 220 
multivariable analysis. However, reduced odds of disease remained significantly associated with a history 221 
of vaccination for CPIV, CAV-2 or CDV with an independent effect of reduced odds of disease in shelter dogs 222 
and dogs from other sources compared with client-owned dogs (Table 2). Further examination of the 223 
vaccination effect indicated that the proportion of dogs with a history of vaccination against CPIV, CAV-2 224 
and CDV reduced significantly as the severity of disease increased (Figure 1).  225 
Significant variations in pathogen seroprevalence were associated with country, source, age, antibody 226 
status and clinical group, but varied by the pathogen studied.   227 
Significant univariable variations in CRCoV seroprevalence were detected by country, age, source, disease 228 
status, clinical score, and CnPnV seropositivity (data not shown). Dogs with antibodies to CRCoV were 229 
significantly less likely to develop respiratory disease (OR: 0.5, p<0.001), with odd ratios of 0.5 (p<0.001) 230 
and 0.4 (p=0.003) for dogs with clinical scores of 2 and 3 respectively compared to dogs with no clinical 231 
signs. Following multivariable analysis, independent effects of country, age and CnPnV antibody status 232 
remained significant (Table 3). Dogs from France and Spain had significantly increased odds of being 233 
seropositive (OR 4.8, p<0.001 and OR 4.1, p<0.001 respectively) compared with dogs from Italy. Dogs were 234 
also significantly more likely to be CRCoV seropositive with increasing age (OR 1.1; p=0.001), or if they were 235 
also seropositive for CnPnV (OR 2.7, p<0.001). 236 
Significant univariable variations in CnPnV seroprevalence were detected by country, source, clinical group, 237 
disease status and clinical score (data not shown).  Dogs with antibodies to CnPnV were significantly less 238 
likely to develop respiratory disease than those without (OR: 0.4, p<0.001), with odds ratios of 0.5 (p<0.001) 239 
and 0.4 (p=0.002) for dogs with clinical scores of 2 and 3 respectively compared to those with no clinical 240 
signs of disease. In multivariable analysis, independent effects of country, source and CRCoV and M. cynos 241 
antibody status remained significant (Table 3). Dogs from France and the Netherlands had 3.4 (p= 0.001) 242 
and 3.7 (p= 0.002) times the odds of being seropositive compared with dogs from Italy. Dogs from shelters 243 
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were almost 3 times (OR 2.8, p<0.001) and dogs from other sources were 8 times (OR 8.0, p<0.001) as likely 244 
to be CnPnV seropositive than client-owned dogs. The odds of being CnPnV seropositive were also 245 
significantly increased in association with CRCoV (OR 2.7, p= <0.001) and M. cynos (OR 1.8, p= 0.005) 246 
seropositivity.  247 
Significant univariable variations in M.cynos seroprevalence were detected in association with country, 248 
source, clinical group, and CRCoV and CnPnV antibody status. No significant association between M. cynos 249 
antibody status and the presence or severity of clinical disease was observed (data not shown). 250 
Independent effects of country, source, clinical group and age remained significant in multivariable analysis 251 
(Table 3). Dogs from Greece, France and Spain were 2.3 (p=0.008), 2.5 (p= 0.012) and 2.2 (p= 0.028) times 252 
as likely to be seropositive for M. cynos as those from Italy, respectively. Shelter dogs were almost twice as 253 
likely as pet dogs to be seropositive for M. cynos (OR 1.8; p=0.024), and convalescent dogs almost three 254 
times as likely to be seropositive than clinically unaffected but exposed dogs (OR 2.8; p=<0.001). The odds 255 
of M. cynos seropositivity also increased with age (OR 1.06; p= 0.024). 256 
The overall seroprevalence of Influenza A was 2.7% (6/220; 95% CI: 1.0-5.8%) with good correlation 257 
between the two ELISA protocols used. The small number of seropositive dogs precluded further statistical 258 
analysis. However, of the six positive dogs five were from a shelter (5/114; 4.4%) and one was client-owned 259 
(1/91; 1.1%). Three were acute with mild signs of clinical disease, two convalescent with no clinical signs of 260 
disease, and one healthy but exposed.  261 
Significant variations in pathogen presence were associated with country, source, clinical score and 262 
antibody status, but varied by the pathogen studied.  263 
Significant univariable variations in CRCoV presence were detected with country, age, clinical score, CRCoV 264 
and CnPnV seropositivity (data not shown). Independent associations with country, clinical score and the 265 
presence of CRCoV antibody remained significant in multivariable analysis (Table 4). Dogs from Greece (OR 266 
12.2; p= 0.02), Hungary (OR 8.9; p= 0.045), France (OR 28; p= 0.002) and Spain (OR 22.5; p= 0.004), at 267 
significantly increased odds of CRCoV positivity compared with dogs from Italy.  Dogs with severe clinical 268 
signs were 3.5 times as likely to be positive for CRCoV as those with no signs of clinical disease (p=0.029), 269 
but were almost half as likely to be positive for CRCoV if they had antibodies to the virus (OR 0.4; p=0.015). 270 
Significant univariable variations in CnPnV presence were detected with country, source and clinical score, 271 
but not with the presence or absence of CnPnV antibody (data not shown). Independent effects of country, 272 
clinical score and CRCoV status remained significant in multivariable analysis (Table 4). Dogs from Hungary 273 
(OR 2.3; p= 0.007) had twice the odds of CnPnV positivity as dogs from Italy. The presence of CRCoV was 274 
associated with a two-fold increase in the odds of CnPnV presence (OR 2.0, p=0.040) and dogs with severe 275 
clinical disease had more than twice the odds of CnPnV positivity as those with no clinical disease (p=0.029). 276 
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Overall 47.9% (n=271/566, CI) of dogs were positive for Mycoplasma Spp. and 0.9% (n=5/566, CI) were 277 
positive for M. cynos (data not shown). The small number of M. cynos positive dogs (n=5) precluded further 278 
analysis. However, four were shelter dogs and one was client-owned. Three had severe respiratory signs 279 
(one requiring euthanasia) whilst two dogs were non-clinical. The trachea, lung, bronchial lymph node, 280 
palatine tonsil and thymus from the euthanized dog were analysed and all, with the exception of the lung, 281 
were positive for M. cynos. 282 
None of the 511 dogs screened for the presence of Influenza A by PCR were positive (data not shown). 283 
Discussion 284 
This study examined the occurrence of CIRD, and four of the most important emerging pathogens 285 
associated with the disease in different dog populations across Europe. Key variables (e.g. clinical 286 
presentation, housing, vaccination etc.) and their relationship with disease occurrence, severity, pathogen 287 
exposure and presence were also analysed.   288 
Overall clinical disease occurred in approximately two-thirds of the dogs, with variations in the rate of 289 
occurrence and severity predominantly associated with housing and vaccination history. Whilst CIRD is 290 
generally regarded as a disease of kennelled dogs as shown here, we have also provided substantial 291 
evidence of CIRD in pet (client-owned) dogs, many of which had moderate to severe signs of disease, 292 
highlighting the need for further consideration of pet dogs in the occurrence and spread of CIRD, and the 293 
potential risk factors associated with this group (e.g. multi-dog households, attendance at dog training, 294 
doggy day care, recent boarding or kennelling). However, the high rate of CIRD observed in client-owned 295 
dogs, compared to kennelled dogs, is most likely explained by an inherent sampling bias. Healthy client-296 
owned dogs are unlikely to have been presented or sampled as part of a normal veterinary investigation, 297 
except in some cases of multi-dog households,  doggy day care etc. where CIRD has been problematic. In 298 
contrast, sampling of apparently healthy dogs in kennelled environments often forms part of a standard 299 
outbreak investigation.  300 
Vaccination therefore is likely to have had the biggest influence on the occurrence and severity of disease 301 
in this study. Within the EU it is recommended that dogs are routinely vaccinated against CAV-2 and CDV 302 
as part of the core vaccinations they receive from puppyhood. The modified-live virus vaccines are 303 
administered parenterally, and are highly efficacious (Day et al., 2016).  Some core vaccine formulations 304 
include CPIV but not Bb, and whilst separate modified-live intranasal vaccines for Bb and CPIV are availaible 305 
they tend to be administered only to high risk dogs (i.e. during periods of kennelling). Studies of CPIV and 306 
Bb vaccine efficacy are regulated by European monographs, requiring specific efficacy and safety 307 
requirmemnts including the onset and duration of immunity. However, published studies are limited and 308 
there is debate on the differing efficacies demonstrated (Day et al., 2016; Ellis, 2015; Ellis and Krakowka, 309 
2012; Mitchell and Brownlie, 2015) .  310 
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Here, a history of vaccination against the classic CIRD-associated pathogens CDV, CAV-2 and CPIV, 311 
significantly reduced the occurrence and severity of disease. However, vaccination against Bb did not, 312 
although this could be due to the small number of Bb vaccinated dogs (n=66) in this study. Despite evidence 313 
of a protective effect substantial proportions of CDV, CAV-2 and CPIV vaccinated dogs remained affected 314 
by CIRD, many with severe clinical signs, supporting the widely accepted view that vaccination against these 315 
key agents may reduce disease occurrence and severity in some individuals or outbreaks, but is often poorly 316 
effective in others. Differences may be a result of vaccine formulation or protocol used, the biological 317 
properties and characteristics of the agent and host, or the involvement of newly identified or emerging 318 
pathogens (Erles et al., 2004; Priestnall et al., 2014) 319 
Whilst these first two points fall beyond the scope of this study, in examining four of the most important 320 
emerging CIRD pathogens it is clear their role in CIRD may be significant for both kennelled and pet dogs. 321 
In particular CRCoV and CnPnV were highly prevalent across the different dog populations studied and their 322 
presence was positively associated with an increased occurrence and severity of clinical disease. The 323 
presence and involvement of M. cynos and influenza A in CIRD was however less apparent.  324 
Almost half the dogs in this study were seropositive for CRCoV and 7.7% were positive for the virus, 325 
consistent with published data (Erles et al., 2003; Priestnall et al., 2006). Multivariable analysis  showed 326 
that the likelihood of dogs having antibodies to CRCoV increased with age, and those with antibodies were 327 
significantly less likely to be positive for the virus. Dogs with increasing disease severity were significantly 328 
more likely to be positive for CRCoV. Dogs with antibodies to CRCoV that developed CIRD were less likely 329 
to develop the more severe clinical signs of disease. Younger dogs (less likely to have antibodies to CRCoV) 330 
were more likely to be infected with CRCoV, and had a greater rate of occurrence of CIRD, and developed 331 
more severe clinical signs.  These findings are consistent with previously published data (Erles et al., 2004; 332 
Erles et al., 2003; Mitchell et al., 2013a), and strengthen the evidence for a causal relationship between 333 
CRCoV infection and CIRD, as well as for the protective effect of CRCoV antibodies against both CRCoV 334 
infection and clinical signs of CIRD in general. Whilst evidence of CRCoV in pet dogs has been reported 335 
previously (Mochizuki et al., 2008; Priestnall et al., 2006) this is the first study to link infection to clinical 336 
disease in this group. 337 
Compared to CRCoV similar overall levels of CnPnV seropositivity (41.7%), but higher detection rates 338 
(23.4%) of CnPnV were observed and are consistent with published data (Mitchell et al., 2013b). Antibodies 339 
to CnPnV were detected in dogs from all three sources, demonstrating the susceptibility of both pet and 340 
kennelled dogs to this virus. Although shelter dogs and dogs from ‘other sources’ had significantly increased 341 
odds of being positive compared to pet dogs, the higher seroprevelce observed in dogs from ‘other sources’ 342 
is most likely due to the samples being derived predominantly from an outbreak of CIRD in a single 343 
veterinary hospital, where, 96% of dogs were seropositive and 33% were positive for the virus.  344 
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Dogs were significantly more likely to be CnPnV seropositive if they were also seropositive for CRCoV (and 345 
vice versa) and M. cynos, suggesting frequent co-infection, or co-circulation of one or more of these 346 
pathogens. In further support of this, dogs were significantly more likely to be positive for CnPnV (by PCR) 347 
if they were also positive for CRCoV (by PCR). Although only 17 such cases were observed in this study, 348 
precluding further analysis, CIRD is increasingly being considered as a complex infection where multiple 349 
agents act sequentially or synergistically to cause disease, and similar disease complexes in humans are the 350 
subject of several reviews Eg:(Bosch et al., 2013). It is likely therefore that co-infections with both the classic 351 
and  novel agents of CIRD will contribute the increased likelihood of disease onset, severity and duration 352 
of CIRD. Given the limited amount work in the field that currently addresses this point however, this should 353 
be an important focus of future.   354 
Dogs with increasing disease severity were significantly more likely to be positive for CnPnV, supporting a 355 
causal relationship with CIRD (Glineur et al., 2013; Mitchell et al., 2013b). Following multivariable analysis 356 
no significant relationship between the presence of CnPnV antibodies and infection or disease occurrence 357 
was observed. This relationship was however significant at the univariable level consistant with other 358 
published data (Mitchell et al., 2013b), suggesting that whilst CnPnV specific antibodies may confer some 359 
degree of protection, this was confounded in this instance by the effects of other factors. That said, it is 360 
well documented that antibody mediated immunity for related human and bovine respiratory syncytial 361 
viruses is poor, and individuals may be repeatedly re-infected throughout their lifetime with clinical signs 362 
of respiratory disease (Falsey, 2007; Hall et al., 1976; Van der Poel et al., 1993). A number of key 363 
pneumovirus features enable them to evade and modify host immune responses as reviwed by (Collins and 364 
Melero, 2011), and as such it would be vital to assess the genetic and antigenic diversity of circulating 365 
CnPnV strains to better understand CnPnV ecology and inform vaccine design and development. 366 
Although studies are limited, M. cynos also represents a potentially important agent in the development 367 
and persistence of CIRD (Chalker et al., 2004; Rosendal, 1972). This is the first study to examine the 368 
seroprevalence of M. cynos, and overall 45% of dogs were seropositive, comparable to that of CRCoV and 369 
CnPnV. In multivariable analysis increased odds of M. cynos seropositivity were seen in shelter dogs 370 
(compared to pet dogs), and convalescent (compared to clinically unaffected) dogs and with age.  371 
Whilst the seropositivity suggests exposure, very few dogs with M. cynos itself (n=5) were detected. Of 372 
those that were, three had severe respiratory signs but two were clinically unaffected.  Given the limited 373 
number of positive cases in this study it is not possible to comment on the prevalence of M. cynos or its 374 
relationship with clinical disease. However it is worth considering the limitations of the study which may 375 
have influenced this finding. Firstly, several mycoplasma species are carried by dogs, often as part of their 376 
normal respiratory flora (Chalker, 2005), however very limited data is available regarding their serological 377 
cross-reactivity (Rosendal, 1975). The possibility exists therefore that the use of whole cell ELISA antigen in 378 
this study may have resulted in an overestimate in M. cynos seropositivity. Secondly, oropharyngeal swabs 379 
 Page 12 of 19 
 
collected as part of a standard veterinary investigation of CIRD were analysed. Previously respiratory tissues 380 
were shown to yield a much higher recovery rate of M. cynos (99.7-23.9%) compared to oropharyngeal 381 
swabs (0-0.9%) (Chalker et al., 2004), and indeed studies that have implicated M. cynos in CIRD were based 382 
on tissue sampling, particularly of the lower respiratory tract (Hong and Kim, 2012; Zeugswetter et al., 383 
2007), the level of M. cynos detected in this study may therefore have been vastly underestimated and 384 
highlights an important consideration for the study of M.cynos in living dogs. 385 
Influenza A (H3N8) caused significant respiratory disease in dogs in north America (Anderson et al., 2013; 386 
Crawford et al., 2005) with an estimated seroprevalence of 49% in high risk populations (Anderson et al., 387 
2013). Subsequent studies from North and Central America and Asia have also identified a number of other 388 
influenza A subtypes which infect and cause disease in dogs, some of which have undergone cross-species 389 
transmission, including possible transmission between dogs and humans (Lin et al., 2012; Song et al., 2008; 390 
Song et al., 2012; Songserm et al., 2006). Assays were therefore selected on the basis that they would allow 391 
for the broad detection of Influenza A rather than specific subtypes (Damiani et al., 2012; Ellis and Zambon, 392 
2001).In agreement with other recently published European studies (Damiani et al., 2012; Dundon et al., 393 
2010) however very little evidence of influenza A was found in this study. All of the dogs were negative for 394 
Influenza A by PCR, and only 2.7% had evidence of exposure via antibody detection. Whilst influenza A 395 
appears relatively insignificant in the European dog population at present, given its rapid spread across 396 
north America and Asia, the increasing number of influenza A subtypes detected in dogs, and the increased 397 
movement of dogs into and across Europe, it may be only  be a matter of time before it makes its 398 
appearance. Moreover, the co-existence of multiple types of influenza in dogs, with the potential to cross-399 
species, should underline the importance of continued vigilance by both the veterinary and medical 400 
communities.  401 
Our current understanding of the true prevalence and complexity of CIRD is limited by a lack of 402 
comprehensive investigations into causative agents and associated risk factors. This study, which has begun 403 
to unpick some of these key areas, is one of the largest studies undertaken in the field to date. Findings 404 
highlight the need for a far greater consideration of pet dogs and other dog populations, the role of current 405 
vaccine formulations and strategies in preventing and managing disease outbreaks, and the impact of 406 
classic and newly identified pathogens on disease onset, development and persistence. For pathogens such 407 
as CRCoV and CnPnV, the emerging data provide a clearly identifiable link with CIRD. However continued 408 
effort is required to characterise the epidemiology and pathogenesis of more elusive pathogens such as M. 409 
cynos,  to ensure that they are not underestimated or overlooked.  410 
Acknowledgements 411 
Sample collection and analysis for CRCoV, M. cynos and influenza A virus was funded by Zoetis Animal 412 
Health. Screening for canine pneumovirus was supported by a grant awarded to Judy A. Mitchell and Joe 413 
Brownlie by the Petplan Charitable Trust. The authors would also like to thank C. Murrell and Y. Alver for 414 
technical assistance, and L. Harbour for administrative support. 415 
 Page 13 of 19 
 
References 416 
Anderson, T.C., Crawford, P.C., Dubovi, E.J., Gibbs, E.P., Hernandez, J.A., 2013. Prevalence of and 417 
exposure factors for seropositivity to H3N8 canine influenza virus in dogs with influenza-like 418 
illness in the United States. J Am Vet Med Assoc 242, 209-216. 419 
Appel, M.J., Binn, L.N., 1987. Canine infectious tracheobronchitis short review: kennel cough. In: Virus 420 
infections of Carnivors 421 
Elseiver Science Publishing Co, New York, 201-211 pp. 422 
Appel, M.J., Percy, D.H., 1970. SV-5-like parainfluenza virus in dogs. J Am Vet Med Assoc 156, 1778-1781. 423 
Bemis, D.A., 1992. Bordetella and Mycoplasma respiratory infections in dogs and cats. Vet Clin North Am 424 
Small Anim Pract 22, 1173-1186. 425 
Bosch, A.A., Biesbroek, G., Trzcinski, K., Sanders, E.A., Bogaert, D., 2013. Viral and bacterial interactions in 426 
the upper respiratory tract. PLoS pathogens 9, e1003057. 427 
Chalker, V.J., 2005. Canine mycoplasmas. Res Vet Sci 79, 1-8. 428 
Chalker, V.J., Owen, W.M., Paterson, C., Barker, E., Brooks, H., Rycroft, A.N., Brownlie, J., 2004. 429 
Mycoplasmas associated with canine infectious respiratory disease. Microbiology 150, 3491-430 
3497. 431 
Collins, P.L., Melero, J.A., 2011. Progress in understanding and controlling respiratory syncytial virus: still 432 
crazy after all these years. Virus Res 162, 80-99. 433 
Crawford, P.C., Dubovi, E.J., Castleman, W.L., Stephenson, I., Gibbs, E.P., Chen, L., Smith, C., Hill, R.C., 434 
Ferro, P., Pompey, J., Bright, R.A., Medina, M.J., Johnson, C.M., Olsen, C.W., Cox, N.J., Klimov, A.I., 435 
Katz, J.M., Donis, R.O., 2005. Transmission of equine influenza virus to dogs. Science 310, 482-436 
485. 437 
Damiani, A.M., Kalthoff, D., Beer, M., Muller, E., Osterrieder, N., 2012. Serological survey in dogs and cats 438 
for influenza A(H1N1)pdm09 in Germany. Zoonoses and public health 59, 549-552. 439 
Day, M.J., Horzinek, M.C., Schultz, R.D., Squires, R.A., Vaccination Guidelines Group of the World Small 440 
Animal Veterinary, A., 2016. WSAVA Guidelines for the vaccination of dogs and cats. J Small Anim 441 
Pract 57, E1-E45. 442 
Decaro, N., Mari, V., Larocca, V., Losurdo, M., Lanave, G., Lucente, M.S., Corrente, M., Catella, C., Bo, S., 443 
Elia, G., Torre, G., Grandolfo, E., Martella, V., Buonavoglia, C., 2016. Molecular surveillance of 444 
traditional and emerging pathogens associated with canine infectious respiratory disease. Vet 445 
Microbiol 192, 21-25. 446 
Ditchfield, J., Macpherson, L.W., Zbitnew, A., 1962. Association of Canine Adenovirus (Toronto A 26/61) 447 
with an Outbreak of Laryngotracheitis ("Kennel Cough"): A Preliminary Report. Can Vet J 3, 238-448 
247. 449 
Dundon, W.G., De Benedictis, P., Viale, E., Capua, I., 2010. Serologic evidence of pandemic (H1N1) 2009 450 
infection in dogs, Italy. Emerg Infect Dis 16, 2019-2021. 451 
Ellis, J.A., 2015. How well do vaccines for Bordetella bronchiseptica work in dogs? A critical review of the 452 
literature 1977-2014. Vet J 204, 5-16. 453 
Ellis, J.A., Krakowka, G.S., 2012. A review of canine parainfluenza virus infection in dogs. J Am Vet Med 454 
Assoc 240, 273-284. 455 
Ellis, J.S., Zambon, M.C., 2001. Combined PCR-heteroduplex mobility assay for detection and 456 
differentiation of influenza A viruses from different animal species. J Clin Microbiol 39, 4097-457 
4102. 458 
Erles, K., Dubovi, E.J., Brooks, H.W., Brownlie, J., 2004. Longitudinal study of viruses associated with 459 
canine infectious respiratory disease. J Clin Microbiol 42, 4524-4529. 460 
Erles, K., Toomey, C., Brooks, H.W., Brownlie, J., 2003. Detection of a group 2 coronavirus in dogs with 461 
canine infectious respiratory disease. Virology 310, 216-223. 462 
Falsey, A.R., 2007. Respiratory syncytial virus infection in adults. Seminars in respiratory and critical care 463 
medicine 28, 171-181. 464 
Glineur, S.F., Renshaw, R.W., Percopo, C.M., Dyer, K.D., Dubovi, E.J., Domachowske, J.B., Rosenberg, H.F., 465 
2013. Novel pneumoviruses (PnVs): Evolution and inflammatory pathology. Virology 443, 257-466 
264. 467 
Hall, C.B., Geiman, J.M., Biggar, R., Kotok, D.I., Hogan, P.M., Douglas, G.R., Jr., 1976. Respiratory syncytial 468 
virus infections within families. N Engl J Med 294, 414-419. 469 
 Page 14 of 19 
 
Hong, S., Kim, O., 2012. Molecular identification of Mycoplasma cynos from laboratory beagle dogs with 470 
respiratory disease. Laboratory animal research 28, 61-66. 471 
Kobayashi, H., Yamamoto, K., Eguchi, M., Kubo, M., Nakagami, S., Wakisaka, S., Kaizuka, M., Ishii, H., 472 
1995. Rapid detection of mycoplasma contamination in cell cultures by enzymatic detection of 473 
polymerase chain reaction (PCR) products. J Vet Med Sci 57, 769-771. 474 
Lin, D., Sun, S., Du, L., Ma, J., Fan, L., Pu, J., Sun, Y., Zhao, J., Sun, H., Liu, J., 2012. Natural and 475 
experimental infection of dogs with pandemic H1N1/2009 influenza virus. J Gen Virol 93, 119-476 
123. 477 
Mitchell, J.A., Brooks, H.W., Szladovits, B., Erles, K., Gibbons, R., Shields, S., Brownlie, J., 2013a. Tropism 478 
and pathological findings associated with canine respiratory coronavirus (CRCoV). Vet Microbiol 479 
162, 582-594. 480 
Mitchell, J.A., Brownlie, J., 2015. The challenges in developing effective canine infectious respiratory 481 
disease vaccines. The Journal of pharmacy and pharmacology 67, 372-381. 482 
Mitchell, J.A., Cardwell, J.M., Renshaw, R.W., Dubovi, E.J., Brownlie, J., 2013b. Detection of canine 483 
pneumovirus in dogs with canine infectious respiratory disease. J Clin Microbiol 51, 4112-4119. 484 
Mochizuki, M., Yachi, A., Ohshima, T., Ohuchi, A., Ishida, T., 2008. Etiologic study of upper respiratory 485 
infections of household dogs. J Vet Med Sci 70, 563-569. 486 
Pratelli, A., Colao, V., 2014. A population prevalence study on influenza infection in dogs in Southern Italy. 487 
New Microbiol 37, 277-283. 488 
Priestnall, S.L., Brownlie, J., Dubovi, E.J., Erles, K., 2006. Serological prevalence of canine respiratory 489 
coronavirus. Vet Microbiol 115, 43-53. 490 
Priestnall, S.L., Mitchell, J.A., Walker, C.A., Erles, K., Brownlie, J., 2014. New and emerging pathogens in 491 
canine infectious respiratory disease. Vet Pathol 51, 492-504. 492 
Renshaw, R.W., Zylich, N.C., Laverack, M.A., Glaser, A.L., Dubovi, E.J., 2010. Pneumovirus in dogs with 493 
acute respiratory disease. Emerg Infect Dis 16, 993-995. 494 
Rosendal, S., 1972. Mycoplasmas as a possible cause of enzootic pneumonia in dogs. Acta veterinaria 495 
Scandinavica 13, 137-139. 496 
Rosendal, S., 1975. Canine mycoplasmas: serological studies of type and reference strains, with a 497 
proposal for the new species, Mycoplasma opalescens. Acta pathologica et microbiologica 498 
Scandinavica. Section B, Microbiology 83, 463-470. 499 
Song, D., Kang, B., Lee, C., Jung, K., Ha, G., Kang, D., Park, S., Park, B., Oh, J., 2008. Transmission of avian 500 
influenza virus (H3N2) to dogs. Emerg Infect Dis 14, 741-746. 501 
Song, D., Moon, H.J., An, D.J., Jeoung, H.Y., Kim, H., Yeom, M.J., Hong, M., Nam, J.H., Park, S.J., Park, B.K., 502 
Oh, J.S., Song, M., Webster, R.G., Kim, J.K., Kang, B.K., 2012. A novel reassortant canine H3N1 503 
influenza virus between pandemic H1N1 and canine H3N2 influenza viruses in Korea. J Gen Virol 504 
93, 551-554. 505 
Songserm, T., Amonsin, A., Jam-on, R., Sae-Heng, N., Pariyothorn, N., Payungporn, S., Theamboonlers, A., 506 
Chutinimitkul, S., Thanawongnuwech, R., Poovorawan, Y., 2006. Fatal avian influenza A H5N1 in a 507 
dog. Emerg Infect Dis 12, 1744-1747. 508 
Van der Poel, W.H., Kramps, J.A., Middel, W.G., Van Oirschot, J.T., Brand, A., 1993. Dynamics of bovine 509 
respiratory syncytial virus infections: a longitudinal epidemiological study in dairy herds. Arch 510 
Virol 133, 309-321. 511 
Zeugswetter, F., Weissenbock, H., Shibly, S., Hassan, J., Spergser, J., 2007. Lethal bronchopneumonia 512 
caused by Mycoplasma cynos in a litter of golden retriever puppies. Vet Rec 161, 626-627. 513 
 514 
  515 
 516 
 517 
 518 
 519 
 Page 15 of 19 
 
Table 1: Study population and sample distribution 520 
 Variable 
 
Seropositive 
Pathogen 
detected 
 CRCoV  CnPnV M. cynos  CRCoV CnPnV 
Dogs (n=525) (n=559) (n=555) 
n % n % n % n % n % n % 
 Total*   
572 100 247 47 219 41.7 236 45 43 7.7 130 23.4 
Source 
Client 
  
261 45.6 86 36.7 51 21.8 92 39.3 20 7.9 46 18.3 
Shelter 
  
264 46.2 139 55.6 137 54.8 137 54.8 21 8.1 73 28.2 
Other 
  
47 8.2 22 53.7 31 75.6 7 17 2 4.4 11 24.4 
Clinical Group 
Unaffected 138 24.1 73 55.3 67 50.8 55 41.7 8 5.9 28 20.6 
Acute 
  
282 49.3 109 42.9 90 35.4 97 38.2 27 9.8 60 22.2 
Convalescent 152 26.6 65 46.8 62 44.6 84 60.4 8 5.4 42 28.2 
Country 
Italy 
  
130 22.7 37 31.9 25 21.5 38 32.8 4 3.1 22 16.9 
Greece 
  
112 19.6 37 38.5 26 27.1 50 52.1 9 8.6 23 21.9 
Hungary 
  
109 19 38 39.2 42 43.3 50 51.5 8 7.4 34 32.4 
France 
  
101 17.7 70 72.2 68 70.1 60 61.9 11 11.5 24 25.3 
Spain 
  
61 10.7 39 63.9 23 37.7 26 42.6 3 4.9 9 14.8 
Netherlands 59 10.3 26 44.8 35 60.3 12 20.7 8 13.6 18 30.5 
Severity Score 
1 (healthy) 191 33.4 108 59.3 100 55 87 47.8 11 5.9 42 22.5 
2 (mild-moderate) 317 55.4 119 41.3 102 35.4 121 42 22 7 67 21.5 
3 (severe) 64 11.2 20 36.4 17 30.9 28 51 10 17 21 37.5 
Disease 
N 
  
191 33.4 108 59.3 100 54.9 87 47.8 11 5.9 42 22.5 
Y 
  
381 66.6 139 40.5 119 34.7 149 43.4 32 8.6 88 23.9 
Vaccination 
CDV (n=403)  
N 
72 17.9 - - - - - - - - - - 
Y 
331 82.1 - - - - - - - - - - 
CAdV (n=405)  
N 
87 21.5 - - - - - - - - - - 
Y 
318 78.5 - - - - - - - - - - 
CPIV (n=381)  
N 
149 39.1 - - - - - - - - - - 
Y 
232 60.9 - - - - - - - - - - 
Bb (n=307) 
N 
241 78.5 - - - - - - - - - - 
Y 
66 21.5 - - - - - - - - - - 
 521 
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Table 2: Final multivariable model for presence of clinical disease (N=406). 522 
Variable  OR p 95% CI 
Source 
Client Ref - - - 
Shelter 0.1 <0.001 0.06 0.19 
Other 0.22 <0.001 0.1 0.45 
Vaccination  
(CPIV, CAV-2, CDV) 
N Ref - - - 
Y 0.3 0.002 0.15 0.66 
 523 
 524 
 525 
 526 
 527 
 528 
 529 
 530 
 531 
 532 
 533 
 534 
 535 
 536 
 537 
 538 
 539 
 540 
 541 
 542 
 543 
 544 
 545 
 546 
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Table 3: Final multivariable models for pathogen seropositivity.  547 
Pathogen Variable  OR p 95% CI 
C
R
C
o
V
 
(N
=4
9
6
) Country 
Italy Ref    
Greece 1.6 0.126 0.87 2.97 
Hungary 1.4 0.331 0.73 2.51 
France 4.8 <0.001 2.34 9.69 
Spain 4.1 <0.001 2.06 8.34 
Netherlands 1.5 0.289 0.72 3.00 
CnPnV IgG 
Negative Ref    
Positive 2.7 <0.001 1.77 4.00 
Age  1.1 0.001 1.04 1.17 
C
n
P
n
V
 
(N
=5
2
5
) 
Country 
Italy Ref    
Greece 1.4 0.331 0.71 2.81 
Hungary 1.6 0.151 0.83 3.17 
France 3.4 0.001 1.67 6.93 
Spain 1.7 0.192 0.75 3.92 
Netherlands 3.7 0.002 1.64 8.22 
Source 
Client Ref    
Shelter 2.8 <0.001 1.61 4.87 
Other 8.0 <0.001 3.33 
19.2
6 
CRCoV IgG 
Negative Ref    
Positive 2.7 <0.001 1.79 4.08 
M. cynos IgG 
Negative Ref    
Positive 1.8 0.005 1.20 2.76 
M
. c
yn
o
s 
(N
=4
9
6
) 
Country 
Italy Ref    
Greece 2.3 0.008 1.23 4.16 
Hungary 1.6 0.171 0.82 3.03 
France 2.5 0.012 1.22 5.27 
Spain 2.2 0.028 1.08 4.46 
Netherlands 0.7 0.334 0.29 1.51 
Source 
Client Ref    
Shelter 1.8 0.024 1.08 3.15 
Other 0.5 0.126 0.18 1.23 
Clinical Group 
Clinically 
unaffected 
Ref    
Acute 1.3 0.287 0.79 2.17 
Convalescent 2.8 <0.001 1.60 4.87 
Age  1.07 0.024 1.00 1.13 
 548 
 549 
 550 
 551 
 552 
 553 
 554 
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Table 4: Final multivariable models for pathogen detection.  555 
Pathogen Variable  OR p value 95% CI 
C
R
C
o
V
 
(N
=5
1
7
) 
Country 
Italy Ref    
Greece 12.2 0.02 1.48 100.27 
Hungary 8.9 0.045 1.05 76.62 
France 28 0.002 3.32 236.08 
Spain 8.7 0.066 0.86 87.34 
Netherlands 22.5 0.004 2.71 187.35 
Severity 
Score 
1 Ref    
2 1.9 0.155 0.78 4.51 
3 3.5 0.029 1.13 10.59 
CRCoV IgG 
Negative Ref    
Positive 0.4 0.015 0.17 0.82 
C
n
P
n
V
 
(N
=5
5
5
) 
Country 
Italy Ref    
Greece 1.3 0.409 0.68 2.55 
Hungary 2.3 0.007 1.26 4.40 
France 1.7 0.127 0.85 3.40 
Spain 0.9 0.762 0.37 2.05 
Netherlands 2.0 0.061 0.97 4.21 
Severity 
Score 
1 Ref    
2 1.1 0.803 0.66 1.69 
3 2.1 0.029 1.07 4.20 
CRCoV PCR 
Negative Ref    
Positive 2.03 0.040 1.03 3.98 
 556 
 557 
 558 
 559 
 560 
 561 
 562 
 563 
 564 
 565 
 566 
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 568 
 569 
Figure 1: Proportion of vaccinated dogs with different clinical disease severity scores. 570 
Vaccinations: (Bb) Boredetella bronchiseptica, (CPIV) canine parainfluenza, (CAV-2) canine adenovirus-2, 571 
(CDV) canine distemper virus. The disease severity score is indicted on the x-axis by 1) Healthy, 2) mild to 572 
moderate, and 3) Severe respiratory disease.  Error bars show 95% confidence interval. *Chi-squared/ 573 
Fisher’s exact test p-value.  574 
 575 
